BioMedix receives U.S. patent titled, 'System and Method for Testing for Cardiovascular Disease'

BioMedix™, a leader in providing integrated Health Information Technology (HIT) products and services, has been awarded a U.S. Patent recognizing its innovative solutions and methods for detecting and managing cardiovascular disease.

On July 19, 2011, the United States Patent & Trademark Office issued U.S. Patent Number 7,983,930, entitled "System and Method for Testing for Cardiovascular Disease," crediting BioMedix™ President & CEO John Romans as inventor. The patent is now part of the growing portfolio of BioMedix™ intellectual property on innovative medical technologies, addressing testing, diagnosis and administrative processing across remote locations. The underlying concept, comprised of a collaborative care model utilizing the integrated suite of BioMedix™ solutions, facilitates partnership between primary care facilities and specialists, taking advantage of the specialists' expertise while still allowing testing to be easily performed at a variety of accessible test locations.

"This development allows specialists to have a virtual presence in every primary care setting, enabling improved care through cost-effective coordination and collaboration of physicians in different physical locations," stated John Romans.

The initial application of this invention has supported the improved detection, treatment and management of an under-diagnosed and costly vascular condition called Peripheral Artery Disease (P.A.D.). The BioMedix™ collaborative care network reduces time and travel for patient treatment while supporting improved patient outcomes. As part of this advanced web-based platform, BioMedix™ PADnet™ Disease Management System 2.0 provides a turnkey collaborative care solution for finding and managing patients with vascular disease utilizing the BioMedix™ PADnet™+, a non-invasive device for in-office testing. With a disease detection network made up of local hub-and-spoke networks across the country, BioMedix™ products and initiatives aim to address gaps in healthcare and disease detection.

Austen Zuege, shareholder at the intellectual property law firm Kinney & Lange, P.A. in Minneapolis said, "I am pleased to see the issuance of this patent, which demonstrates the high level of innovation at BioMedix™."